AZTR: Azitra Corp Company Value to Net Income

Corporate emblem and logo of Azitra Corp (AZTR)

The price trend for Azitra, Inc. (AZTR), whose business relies on bioengineered proteins and microbiome therapy for Netherton syndrome, as reflected in this GURU.Markets chart, is currently at -0.30. A lack of profitability and dependence on borrowed funds create significant risks should early-stage tests fail. Meanwhile, FDA orphan status protects the company's potential within the genetic engineering niche.

Azitra, Inc. (AZTR) Price to Earnings Ratio: for the period 03/17/2024 - 11/11/2026

Analytical breakdowns for Azitra, Inc.

- price and consensus price forecast:
Stock Price azitrainc.com|AZTR - Consensus Target
- market capitalization information:
Market Value Azitra, Inc.|AZTR - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share Azitra|AZTR - Company Book Value|Market Capitalization to Book Value Ratio azitrainc.com|AZTR - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Coefficient Azitra, Inc.|AZTR - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Azitra Corporation|AZTR - Company Aggregate Debts|Debts to Book Capitalization Azitra, Inc.|AZTR - Company Long-Term Liabilities|Current Liabilities Azitra|Interim Coverage Ratio azitrainc.com
- earnings and market multiples details:
AZTR - Net Income|Future Net Profit Azitra, Inc.|AZTR - Price to Earnings Ratio|Future Price to Earnings Multiple Azitra Inc|AZTR - PEG Multiple|EV/EBITDA Multiple Azitra, Inc.|AZTR - Operating profit before deduction of amortization|Earnings per share for the trailing year Azitra|AZTR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months azitrainc.com|AZTR - Earnings per share growth in current year|Projected earnings per share growth rate for next year Azitra, Inc.
Summary company analysis:AZTR, azitrainc.com
Manufactured product of azitrainc.com

Azitra, Inc. (AZTR) focuses on developing bacterial therapies for skin pathologies, which requires significant expenditures on clinical trials. This calculation determines the market value of the business relative to its net income, measuring the investment payback period. An analysis of the price-to-earnings ratio reveals the extent of the premium paid for future FDA successes. The indicator's dynamics reflect the balance between speculative optimism and actual profitability. This allows for an assessment of the asset's resilience in the face of high biotech risks.

Competing companies

P/E Multiple krystalbio.com|Price to Earnings Ratio APGE (Apogee Therapeutics, Inc.)|ARQT (Arcutis) - Company Value to Net Income|Price to Earnings Ratio Vericel Corp. VCEL|Business Payback Period Oruka Pharma (ORKA)|SMTI - Price to Earnings Ratio|DBVT - P/E Multiple|SLSN: P/E Multiple|DERM - Business Payback Period|Price to Earnings Ratio Forte Biosciences, Inc|Price to Earnings Multiple EMPG (Empro Corporation)|P/E Multiple SLGL|P/E Multiple reviveprocare.com (AXIL)|Medicus Pharma - Price to Earnings Ratio|VRCA (Verrica Pharmaceuticals Inc) - Market Cap to Net Income|Hoth - P/E Multiple|Business Payback Period Biofrontera Inc. BFRI|VYNE (vynetherapeutics.com) - Price to Earnings Ratio|SNOA: Market Price to Net Income Ratio|Price to Earnings Ratio Quoin Pharmaceuticals Ltd|DRMA: Company Value to Net Income|P/E Multiple ELAB|P/E Multiple Revance Therapeutics Inc (RVNC)